Results 281 to 290 of about 847,478 (341)

Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and Indication.

JAMA Health Forum
Sarpatwari A, Soto MJ, Ganguli I, Sloan CE, Goss F, Sinaiko AD.   +5 more
europepmc   +1 more source

Longitudinal analysis of pupillometry according to type of pharmacotherapy in Parkinson's disease patients. [PDF]

Sci Rep
Bartošová O, Dušek P, Šíma M, Stránský D, Hlaváč J, Růžička E, Šonka K, Slanař O.   +7 more
europepmc   +1 more source

Hyaluronic Acid Hydrogel Implants for Sustained Release of Oxaliplatin and Resiquimod to Prevent Hepatocellular Carcinoma Recurrence Post‐Radiofrequency Ablation

Advanced Science, EarlyView.
Preparation of a biopolymer‐based immune implant (BI) for the sustained release of R848 and oxaliplatin (OXA), enabling immune activation and preventing recurrence after radiofrequency ablation (RFA) treatment in hepatocellular carcinoma (HCC). Abstract Hepatocellular carcinoma (HCC) remains a global challenge due to limited therapies and high ...
Yuezhan Shan, Hongyu Chu, Sheyu Ye, Guofeng Ji, Jiayi Zhao, Xinghui Si, Yumin Zhong, Youmao Tao, Jingwei Shi, Xuedong Fang   +9 more
wiley   +1 more source

Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications. [PDF]

BMC Psychiatry
IsHak WW, Hirsch D, Renteria S, Totlani J, Murphy N, Chang T, Abdelsalam R, Salem M, Meyer A, Keerthana S, Liu A, Contreras L, Tadros E, Hedrick R, Danovitch I, Pechnick RN.   +15 more
europepmc   +1 more source

Intravenous iRGD‐Guided, RBC‐Membrane Camouflaged Lactococcus Lactis Remodels Cold NSCLC and Enhances PD‐1 Blockade

Advanced Science, EarlyView.
This study presents an engineered probiotic platform, iRGD‐mRBC@FOLactis, combining red blood cell membrane cloaking and tumor‐penetrating peptide iRGD for enhanced PD‐1 blockade. The platform improves tumor targeting, immune cell activation and therapeutic efficacy in lung cancer, demonstrating significant promise in overcoming PD‐1/PD‐L1 therapy ...
Chen Chen, Junmeng Zhu, Xiao Liu, Jie Shao, Aoxing Chen, Yi Mei, Xinyin Zhang, Qinyi Chen, Lin Li, Baorui Liu   +9 more
wiley   +1 more source

ARL3 Enhances ERα Stability via USP10 Deubiquitination to Promote Endocrine Resistance and Drive Mitochondrial Metabolic Reprogramming in HR+ Breast Cancer

Advanced Science, EarlyView.
This study identifies ADP‐ribosylation factor‐like protein 3 (ARL3) as a novel chaperone that stabilizes estrogen receptor α (ERα) in breast cancer. ARL3 promotes tumor growth by recruiting USP10 to remove ubiquitin chains from ERα, preventing its degradation.
Han Li, Yang Liu, Zehao Cai, Kang Li, Shun Gao, Ailin Lan, Dan Shu, Kuan He, Xin Liu, Yang Peng, Shipeng Guo, Haochen Yu, Aishun Jin, Meiying Shen, Shengchun Liu   +14 more
wiley   +1 more source

Health care resource utilization and health care costs among digital weight-loss intervention participants and nonparticipants. [PDF]

Obesity (Silver Spring)
Tak C, Thompson P, Morse JL, McCallum M.
europepmc   +1 more source

Integrin‐Piezo1 Axis Drives ECM Remodeling and Invasion of 3D Breast Epithelium

Advanced Science, EarlyView.
Mechanical stiffening of the extracellular matrix around mature mammary acini induces sequential remodeling phases. An early response disrupts the basement membrane and promotes fibronectin secretion, followed by delayed invasion with matrix reorganization and proliferation.
Kabilan Sakthivel, Anna Kotowska, Zhimeng Fan, Ellen Juel Portner, Catherine Merry, Pontus Nordenfelt, Adam Cohen Simonsen, Amanda J. Wright, Vinay S Swaminathan   +8 more
wiley   +1 more source

POTENCY RATIO BETWEEN OPIOID AGONISTS AND PARTIAL AGONISTS

British Journal of Anaesthesia, 1987
openaire   +3 more sources

Molecular Insights into Bromocriptine Binding to GPCRs Within Histamine-Linked Signaling Networks: Network Pharmacology, Pharmacophore Modeling, and Molecular Dynamics Simulation. [PDF]

Int J Mol Sci
Dermawan D, Elbouamri L, Chtita S, Alotaiq N.   +3 more
europepmc   +1 more source